[{"id":"38d96c78-7695-48ef-a4bd-d1c77b87723e","acronym":"NCI-2018-01050","url":"https://clinicaltrials.gov/study/NCT03774472","created_at":"2021-01-18T18:40:19.361Z","updated_at":"2025-02-25T14:15:17.560Z","phase":"Phase 1/2","brief_title":"Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT03774472 - NCI-2018-01050","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • letrozole • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 08/20/2018","start_date":" 08/20/2018","primary_txt":" Primary completion: 04/17/2024","primary_completion_date":" 04/17/2024","study_txt":" Completion: 04/17/2024","study_completion_date":" 04/17/2024","last_update_posted":"2025-02-17"},{"id":"b7222b36-4294-4a60-9a60-79c17a69cc40","acronym":"MEKiAUTO","url":"https://clinicaltrials.gov/study/NCT04214418","created_at":"2021-01-18T20:31:18.521Z","updated_at":"2024-07-02T16:35:17.433Z","phase":"Phase 1/2","brief_title":"Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies","source_id_and_acronym":"NCT04214418 - MEKiAUTO","lead_sponsor":"Columbia University","biomarkers":" KRAS • MSI • NTRK","pipe":" | ","alterations":" KRAS mutation • MSI-H/dMMR • NTRK positive • NTRK fusion","tags":["KRAS • MSI • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • MSI-H/dMMR • NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cotellic (cobimetinib) • hydroxychloroquine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 175","initiation":"Initiation: 02/12/2020","start_date":" 02/12/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-02-28"},{"id":"7f51bdeb-9ca6-4832-abd2-10427a80963f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01023737","created_at":"2021-01-18T04:00:54.593Z","updated_at":"2025-02-25T16:00:13.975Z","phase":"Phase 1","brief_title":"Hydroxychloroquine + Vorinostat in Advanced Solid Tumors","source_id_and_acronym":"NCT01023737","lead_sponsor":"The University of Texas Health Science Center at San Antonio","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • RAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zolinza (vorinostat) • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 11/01/2009","start_date":" 11/01/2009","primary_txt":" Primary completion: 12/05/2017","primary_completion_date":" 12/05/2017","study_txt":" Completion: 01/08/2023","study_completion_date":" 01/08/2023","last_update_posted":"2023-02-13"},{"id":"c3005ef7-71ae-4128-b1ae-282cc4e68429","acronym":"IMMUNONCOVID","url":"https://clinicaltrials.gov/study/NCT04333914","created_at":"2021-01-18T20:59:05.040Z","updated_at":"2024-07-02T16:36:03.152Z","phase":"Phase 2","brief_title":"Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection","source_id_and_acronym":"NCT04333914 - IMMUNONCOVID","lead_sponsor":"Centre Leon Berard","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e avdoralimab (IPH5401) • ezurpimtrostat (GNS561) • monalizumab (IPH2201)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/15/2020","start_date":" 04/15/2020","primary_txt":" Primary completion: 07/06/2021","primary_completion_date":" 07/06/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2022-09-30"},{"id":"aae7c06f-06d4-4061-9a3e-f99e14e9f333","acronym":"","url":"https://clinicaltrials.gov/study/NCT00962845","created_at":"2021-05-06T10:52:31.702Z","updated_at":"2024-07-02T16:36:04.386Z","phase":"Phase 1","brief_title":"Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery","source_id_and_acronym":"NCT00962845","lead_sponsor":"Rutgers, The State University of New Jersey","biomarkers":" BECN1","pipe":"","alterations":" ","tags":["BECN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 05/30/2013","primary_completion_date":" 05/30/2013","study_txt":" Completion: 05/30/2013","study_completion_date":" 05/30/2013","last_update_posted":"2022-09-07"},{"id":"f82a9415-9c44-4b70-ae97-0016379c904a","acronym":"CHLOROTRAMMEL","url":"https://clinicaltrials.gov/study/NCT03979651","created_at":"2021-01-18T19:34:14.508Z","updated_at":"2024-07-02T16:36:45.211Z","phase":"","brief_title":"MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma","source_id_and_acronym":"NCT03979651 - CHLOROTRAMMEL","lead_sponsor":"Hospices Civils de Lyon","biomarkers":" NRAS","pipe":" | ","alterations":" NRAS mutation","tags":["NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • hydroxychloroquine"],"overall_status":"Unknown status","enrollment":" Enrollment 29","initiation":"Initiation: 10/15/2019","start_date":" 10/15/2019","primary_txt":" Primary completion: 03/31/2022","primary_completion_date":" 03/31/2022","study_txt":" Completion: 03/31/2022","study_completion_date":" 03/31/2022","last_update_posted":"2020-05-08"}]